NASDAQ:DCPHDeciphera Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Deciphera Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $43.32 -1.22 (-2.74 %) (As of 04/9/2020 04:00 PM ET) Add Compare Share Today's Range$42.37Now: $43.32▼$46.7550-Day Range$33.63MA: $46.09▼$57.6552-Week Range$19.88Now: $43.32▼$71.11Volume382,436 shsAverage Volume623,334 shsMarket Capitalization$2.41 billionP/E RatioN/ADividend YieldN/ABeta2.11 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingDeciphera Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $65.38, Deciphera Pharmaceuticals has a potential upside of 50.9% from its current price of $43.32.Amount of Analyst CoverageDeciphera Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesDeciphera Pharmaceuticals has received 272 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDeciphera Pharmaceuticals has received 271 “underperform” votes. (Add your “underperform” vote.)Community SentimentDeciphera Pharmaceuticals has received 50.09% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote “Outperform” if you believe DCPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DCPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDeciphera Pharmaceuticals does not currently pay a dividend.Dividend GrowthDeciphera Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Deciphera Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,069,053.00 in company stock.Percentage Held by InsidersOnly 7.02% of the stock of Deciphera Pharmaceuticals is held by insiders.Percentage Held by Institutions63.96% of the stock of Deciphera Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Deciphera Pharmaceuticals are expected to decrease by -22.64% in the coming year, from ($5.30) to ($4.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Deciphera Pharmaceuticals is -9.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Deciphera Pharmaceuticals is -9.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDeciphera Pharmaceuticals has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.59 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DCPH Previous Symbol CUSIPN/A CIK1654151 Webhttp://www.deciphera.com/ Phone781-209-6400Debt Debt-to-Equity Ratio0.03 Current Ratio9.88 Quick Ratio9.88Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$25 million Price / Sales96.42 Cash FlowN/A Price / Cash FlowN/A Book Value$10.71 per share Price / Book4.04Profitability EPS (Most Recent Fiscal Year)($4.48) Net Income$-192,260,000.00 Net MarginsN/A Return on Equity-47.62% Return on Assets-42.68%Miscellaneous Employees112 Outstanding Shares55,645,000Market Cap$2.41 billion Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive DCPH News and Ratings via Email Sign-up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:DCPH Rates by TradingView Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions How has Deciphera Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DCPH stock has decreased by 2.5% and is now trading at $43.32. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Deciphera Pharmaceuticals? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Deciphera Pharmaceuticals. When is Deciphera Pharmaceuticals' next earnings date? Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Deciphera Pharmaceuticals. How were Deciphera Pharmaceuticals' earnings last quarter? Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) issued its quarterly earnings data on Monday, March, 9th. The company reported ($1.31) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.13) by $0.18. View Deciphera Pharmaceuticals' earnings history. What price target have analysts set for DCPH? 13 equities research analysts have issued 12-month price objectives for Deciphera Pharmaceuticals' stock. Their forecasts range from $34.00 to $84.00. On average, they expect Deciphera Pharmaceuticals' share price to reach $65.38 in the next twelve months. This suggests a possible upside of 50.9% from the stock's current price. View analysts' price targets for Deciphera Pharmaceuticals. Has Deciphera Pharmaceuticals been receiving favorable news coverage? Media coverage about DCPH stock has been trending very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Deciphera Pharmaceuticals earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutDeciphera Pharmaceuticals. Are investors shorting Deciphera Pharmaceuticals? Deciphera Pharmaceuticals saw a drop in short interest in March. As of March 13th, there was short interest totaling 2,610,800 shares, a drop of 8.1% from the February 27th total of 2,840,000 shares. Based on an average trading volume of 681,200 shares, the short-interest ratio is currently 3.8 days. Approximately 7.5% of the company's stock are short sold. View Deciphera Pharmaceuticals' Current Options Chain. Who are some of Deciphera Pharmaceuticals' key competitors? Some companies that are related to Deciphera Pharmaceuticals include Beigene (BGNE), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Mylan (MYL), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Forty Seven (FTSV) and Reata Pharmaceuticals (RETA). What other stocks do shareholders of Deciphera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include Ionis Pharmaceuticals (IONS), Allena Pharmaceuticals (ALNA), Immunomedics (IMMU), Viking Therapeutics (VKTX), Alibaba Group (BABA), Amarin (AMRN), Arrowhead Pharmaceuticals (ARWR), Cytokinetics (CYTK), Fate Therapeutics (FATE) and Global Blood Therapeutics (GBT). Who are Deciphera Pharmaceuticals' key executives? Deciphera Pharmaceuticals' management team includes the following people: Dr. Daniel L. Flynn, Exec. VP, Chief Scientific Officer & Founder (Age 64)Mr. Christopher J. Morl, Chief Bus. Officer (Age 60)Countess Steven L. Hoerter, Pres, CEO & Director (Age 48)Mr. Thomas Patrick Kelly J.D., Exec. VP, CFO & Treasurer (Age 48)Dr. Stephen B. Ruddy Ph.D., Chief Technical Officer (Age 55) When did Deciphera Pharmaceuticals IPO? (DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers. What is Deciphera Pharmaceuticals' stock symbol? Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH." How do I buy shares of Deciphera Pharmaceuticals? Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Deciphera Pharmaceuticals' stock price today? One share of DCPH stock can currently be purchased for approximately $43.32. How big of a company is Deciphera Pharmaceuticals? Deciphera Pharmaceuticals has a market capitalization of $2.41 billion and generates $25 million in revenue each year. The company earns $-192,260,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe. View additional information about Deciphera Pharmaceuticals. What is Deciphera Pharmaceuticals' official website? The official website for Deciphera Pharmaceuticals is http://www.deciphera.com/. How can I contact Deciphera Pharmaceuticals? Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: Forex
